KURA vs. DNLI, RXRX, BLTE, CGON, INDV, AGIO, APGE, IDYA, SRPT, and HRMY
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Belite Bio (BLTE), CG Oncology (CGON), Indivior (INDV), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), IDEAYA Biosciences (IDYA), Sarepta Therapeutics (SRPT), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.
Kura Oncology vs. Its Competitors
Kura Oncology (NASDAQ:KURA) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.
Kura Oncology has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Denali Therapeutics' return on equity of -35.90% beat Kura Oncology's return on equity.
92.9% of Denali Therapeutics shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Kura Oncology had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Kura Oncology and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.93 beat Kura Oncology's score of 0.61 indicating that Denali Therapeutics is being referred to more favorably in the news media.
Kura Oncology has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.
Kura Oncology presently has a consensus price target of $24.50, indicating a potential upside of 324.61%. Denali Therapeutics has a consensus price target of $33.71, indicating a potential upside of 140.99%. Given Kura Oncology's higher possible upside, equities analysts plainly believe Kura Oncology is more favorable than Denali Therapeutics.
Summary
Denali Therapeutics beats Kura Oncology on 8 of the 15 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kura Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:KURA) was last updated on 6/30/2025 by MarketBeat.com Staff
Free KURA Stock Alerts